

Financial Tear Sheet

Corporate Profile

We are a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of patients in the physician office setting or operating room who are suffering from chronic sinusitis. Our XprESS family of products is used by ear, nose and throat, or ENT, physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation to treat patients with symptomatic inflammation of the nasal sinuses.

Recent Headlines

06/28/18	Multi-Center Market Research Confirms Nasal Valve Collapse as a Contributor for Most Nasal Obstruction Sufferers
06/19/18	Entellus Medical announces publication of the 1-year results of a randomized controlled trial comparing balloon dilation with medical therapy for treatment of persistent Eustachian tube dysfunction
05/31/18	Entellus Medical Announces Multi-Center Clinical Study Publication Confirming Nasal Obstruction Symptom Improvement from LATERA

Upcoming Events

There are currently no events scheduled.

SEC Filings

FILING DATE	FORM
03/12/18	15-12B
03/08/18	SC 13D/A
03/07/18	SC 13D/A
03/06/18	EFFECT

Corporate Governance

Robert S. White	President and CEO
Brent A. Moen	CFO
Michael H. Rosenthal	Chief Operating Officer
Donald Gonzales, M.D.	Chief Medical Officer
Thomas P. Williamson	Vice President, Commercial Operations

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)